'Total Worldwide Revenues from Drugs to Treat Eye Disorders Will Reach $23.8bn in 2016' Predicts New Visiongain's Report

English
3 Pages
Read
Download
Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

Description

'Total Worldwide Revenues from Drugs to Treat Eye Disorders Will Reach $23.8bn in 2016' Predicts New Visiongain's Report PR Newswire LONDON, October 18, 2012 LONDON, October 18, 2012 /PRNewswire/ -- A new report by Visiongain predicts that total worldwide revenues from drugs to treat eye disorders will reach $23.8bn in 2016. Leading companies will achieve high sales growth from 2012 to 2022. That sales prediction and other forecasts appear in Pharma Leader Series: Top 20 Ophthalmic Drug Manufacturers 2012-2022, published in October 2012. Visiongain is a business information provider based in London, UK. The world market for ophthalmic drugs is a profitable segment of the healthcare market. The market for medicines to treat eye diseases is dominated by large pharma companies, which occupy five of the ten leading ophthalmic manufacturers' positions. The others participants are specialist companies, with three focused entirely on ophthalmic pharmaceutical products. In 2011, the top 10 ophthalmic drug manufacturers accounted for 70.6% of overall world revenues in this sector. US-based manufacturers dominate the ophthalmic drug industry and market, with a new entrant, Regeneron - with its recent launch of Eylea (for wet AMD) - rapidly establishing itself in that market. The overall ophthalmic medicines market is stimulated by a rising prevalence of eye disorders worldwide.

Subjects

Informations

Published by
Reads 11
Language English
Report a problem
'Total Worldwide Revenues from Drugs to Treat Eye Disorders Will Reach $23.8bn in 2016' Predicts New Visiongain's Report
PR Newswire LONDON, October 18, 2012
LONDON,October 18, 2012/PRNewswire/ --
A new report byVisiongainpredicts that total worldwide revenues from drugs to treat eye disorders will reach $23.8bnin 2016. Leading companies will achieve high sales growth from 2012 to 2022. That sales prediction and other forecasts appear inPharma Leader Series: Top 20 Ophthalmic Drug Manufacturers 2012-2022, published in October 2012. Visiongain is a business information provider based in London, UK.
The worldmarketfor ophthalmic drugs is a profitable segment of the healthcare market. The market for medicines to treat eye diseases is dominated by large pharma companies, which occupy five of the ten leading ophthalmic manufacturers' positions. The others participants are specialist companies, with three focused entirely on ophthalmic pharmaceutical products. In 2011, the top 10 ophthalmic drug manufacturers accounted for 70.6% of overall world revenues in this sector. US-based manufacturers dominate the ophthalmic drug industry and market, with a new entrant, Regeneron - with its recent launch of Eylea (for wet AMD) - rapidly establishing itself in that market.
The overall ophthalmic medicines market is stimulated by a rising prevalence of eye disorders worldwide. The main causes of visual impairment and loss in the developed countries are retinal diseases, such as age-related macular degeneration (AMD), diabetic macular (o)edema, and macular (o)edema due to retinal vein occlusion. Worldwide, over 50 million patients are estimated to have AMD, with prevalence rates expected to double by 2020. Glaucoma, the leading cause of irreversible blindness, affects an estimated 70 million people worldwide. Its treatment remains one of the largest segments of the ophthalmic prescription drugs market.
Dr Syed Ahmed, a senior pharma industry analyst in visiongain, said: "The top 20 ophthalmic drug manufacturers are a mix of large cap and mid cap specialist companies. Many of those companies have a long history in the industry, with some having been among the first organisations to launch eye care products. Nevertheless, several leading firms will see their places challenged over the next 10 years. Our strong revenue growth forecast for the ophthalmic drug market shows it to be an attractive proposition from 2012 to 2022, and many new entrants seek to enter that market. Clearly, too, its R&D pipeline is strong and promising.
"Visiongain believes future success for ophthalmic drug manufacturers will depend on launches of new compounds, particularly neuroprotective anti-glaucoma drugs and new delivery systems and formulations, including greater use of sustained-release implant and injection technologies for retinal diseases."
This decade many opportunities for treating eye diseases will occur, with new medicines launched. There are many opportunities for novel drugs. Pharma corporations and specialty healthcare operations will develop and prosper, visiongain's analyses show.
Pharma Leader Series: Top 20 Ophthalmic Drug Manufacturers 2012-2022 adds to visiongain's range of analytical reports on industries and markets in healthcare.
For further information concerning the Visiongain's Pharma Leader Series: Top 20 Ophthalmic Drug Manufacturers 2012-2022 report please visitm/con.aingiois.vmrahP/119/tropeRies--Seradera-Lelaimhpht02O-oT-p-cpt/:w/wwth Drug-Manufacturers-2012-2022
For an executive summary please contact: Sara Peerunsara.peerun@visiongainglobal.comor Tel: +44 (0) 20 7336
Companies Listed
Alcon Laboratories Alimera Sciences Allergan Allergan Pharmaceuticals Ireland American Academy of Ophthalmology (AAO) American Diabetes Association American Society of Retina Specialists (ASRS)
AmpliPhi BioSciences Corporation Asahi Astellas Pharma AstraZeneca Banyu Pharmaceutical Co (currently MSD K.K.) Bausch + Lomb (B&L) Bayer Bayer HealthCare Bayer Yakuhin (Bayer's Japanese subsidiary) Bristol-Myers Squibb BioDiem BioInvent International Cambridge University Centre for Molecular and Vascular Biology, KU Leuven. Chugai CIBA Vision Ciba-Geigy Clinical Data CoMentis CT Freda Daiichi Sankyo EAME countries Eli Lilly Esteve European Medicines Agency (EMEA/EMA) EyeTech Pharmaceuticals (now OSI Pharmaceuticals) Food and Drug Administration (FDA) [US] Forest Laboratories Gene Signal Genentech GenVec Gilead Sciences, GlaxoSmithKline (GSK) Harvard Business School Hoffman La Roche Inspire Pharmaceuticals ISTA Pharmaceuticals Johns Hopkins University KAI Pharmaceuticals Kyorin Pharmaceutical Kyowa Hakko Kirin LEO Pharma Lpath MacuSight Meda Merck & Co. Merial MerLion Pharmaceuticals Ministry for Health, Labor and Welfare [Japan] Molecular Partners Monash University MSD K.K Mylan Seiyaku National Eye Institute (NEI) National Health Service (NHS) National Institute for Health and Clinical Excellence (NICE) Neurotech Nichi-Iko Pharmaceutical Nipro Pharma Nobilon International NovaBay Pharmaceuticals Novagali Pharma Novartis Novartis Institutes for BioMedical Research (NIBR) Oklahoma Medical Research Foundation Ophthotech OPKO Health OSI Pharmaceuticals Othera Pharmaceuticals Oxford BioMedica Oxigene Pfizer Pharmacia Potentia
pSivida Purdue University QLT Quark Regeneron ReVision Therapeutics Roche Sandoz Sanofi Santen Pharmaceutical Co. Senju Pharmaceuticals Science & Technology (Beijing) Co. Senju Pharmaceutical Senju USA Shandong University Shire Sirion Therapeutics Sirnaomics Sun Pharmaceutical Industries Taiyo Yakuhin Takeda TargeGen Teva Pharmaceutical Industries Therapeutic Goods Administration (TGA) ThromboGenics University College London University of Melbourne Upjohn Warburg Pincus Warner-Lambert Watson Pharmaceuticals Wyeth Pharmaceuticals
About visiongain Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.comor call her on +44(0)207-336-6100.